Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Debt-to-EBITDA : -8.63 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Panacea Life Sciences Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Panacea Life Sciences Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $15.21 Mil. Panacea Life Sciences Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $6.64 Mil. Panacea Life Sciences Holdings's annualized EBITDA for the quarter that ended in Mar. 2024 was $-2.53 Mil. Panacea Life Sciences Holdings's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -8.63.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Panacea Life Sciences Holdings's Debt-to-EBITDA or its related term are showing as below:

PLSH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.73 Med: -5.67 Max: -3.54
Current: -4.98

During the past 4 years, the highest Debt-to-EBITDA Ratio of Panacea Life Sciences Holdings was -3.54. The lowest was -7.73. And the median was -5.67.

PLSH's Debt-to-EBITDA is ranked worse than
100% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.715 vs PLSH: -4.98

Panacea Life Sciences Holdings Debt-to-EBITDA Historical Data

The historical data trend for Panacea Life Sciences Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Life Sciences Holdings Debt-to-EBITDA Chart

Panacea Life Sciences Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-6.78

-7.73

-3.54

-4.56

Panacea Life Sciences Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial											-4.88	-4.59	-3.86	-4.00	-8.63

Competitive Comparison of Panacea Life Sciences Holdings's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Panacea Life Sciences Holdings's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Panacea Life Sciences Holdings's Debt-to-EBITDA falls into.

Panacea Life Sciences Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Panacea Life Sciences Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(14.818	+	6.827)	/	-4.746
	=	-4.56

Panacea Life Sciences Holdings's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(15.214	+	6.643)	/	-2.532
	=	-8.63

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Panacea Life Sciences Holdings (OTCPK:PLSH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Panacea Life Sciences Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Panacea Life Sciences Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Panacea Life Sciences Holdings Inc (OTCPK:PLSH) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

5910 S University Boulevard, C18-193, Greenwood Village, CO, USA, 80121

Website

https://www.panacealife.com

Panacea Life Sciences Holdings Inc is a cannabinoid nutraceutical manufacturer and research company that produces natural pharmaceutical alternatives for consumers and pets. It manufactures and sells soft gels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals.

Executives

Leslie Buttorff	director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER	16194 W 45TH DRIVE, GOLDEN CO 80403
Janice Nerger	director	5910 S UNIVERSITY BLVD., C18-193, GREENWOOD VILLAGE CO 80121
Nathan Joel Berman	officer: CONTROLLER & PRIN ACTNG OFCR	16194 W 45TH DRIVE, GOLDEN CO 80403
22nd Century Group, Inc.	10 percent owner	8560 MAIN STREET, SUITE 4, WILLIAMSVILLE NY 14221
Harvey J Kesner	10 percent owner	65 E. 55TH STREET, NEW YORK NY 10022
Lawrence Wert	director	170 NUTTALL RD, RIVERSIDE IL 60546
Chesne Derek Du	officer: Chief Growth Officer	80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Alvaro Daniel Alberttis	director	80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483
Vladislav Yampolsky	director, 10 percent owner	332 PLAZA REAL, BOCA RATON FL 33432
Steven A Schwartz	director	332 PLAZA REAL, BOCA RATON FL 33432
Andrew L. Johnson	officer: Chief Strategy Officer	80 NE 4TH AVE. SUITE 28, DELRAY BEACH FL 33483
Emiliano Angel Aloi	officer: President	510 SUNSHINE DRIVE, DELRAY BEACH FL 33444
Jonathan Gilbert	director, officer: Executive Chairman	36 SYCAMORE LANE, ROSALYN HEIGHTS NY 11577
John C Price	director	4721 IRONTON STREET, BUILDING A, DENVER CO 80239
Kevin James Esval	director	NEURO HITECH INC, ONE PENN PLAZA STE 1503, NEW YORK NY 10019